Zeolitic imidazolate frameworks for sustained checkpoint inhibitor release in cancer immunotherapy Feb. 16, 2021
Phase II study evaluates E-52862 in early treatment of outpatients with mild COVID-19 symptoms Feb. 15, 2021
FDA approves Cosela for myeloprotection in patients with extensive-stage SCLC receiving chemotherapy Feb. 15, 2021
RSS